Announced Thu, 23 Jul · 15:52 IST
Thyrocare Q1 FY27 results: Revenue up 26%, PAT up 39% YoY
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.0%1-day move
₹544.95
prior close
₹560.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+5.4+3.1+1.3+4.2+7.0—————————
Up moveDown movePending
AI summary
Thyrocare Technologies posted Q1 FY27 standalone revenue of Rs 225.66 Cr, up 26.1% YoY from Rs 178.89 Cr. Standalone PAT rose 39.2% to Rs 50.17 Cr from Rs 36.05 Cr. EPS at Rs 3.15 versus Rs 2.27 restated. Consolidated revenue grew 24.3% to Rs 240.02 Cr with PAT up 34.1% at Rs 51.33 Cr. Diagnostic testing segment drove growth at about 27%. Price Waterhouse issued unmodified review. Ernst and Young reappointed internal auditor for FY27.
Likely market impact
Strong double-digit growth in revenue and profit likely positive for stock sentiment; clean audit opinion supports confidence.